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Introduction: Type 1 insulin-like growth factor receptor is
deregulated in solid tumors. Cixutumumab, a monoclonal
antibody that inhibits the activity of type 1 insulin-like
growth factor receptor, was investigated in combination
with pemetrexed/cisplatin in the frontline setting.*Corresponding author.
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stage IV nonsquamous NSCLC and a performance status of
0 to 1 were randomized (1:1) to receive 20 mg/kg cix-
utumumab, 500 mg/m2 pemetrexed, and 75 mg/m2
cisplatin (cixutumumab [n ¼ 87]) or pemetrexed and
cisplatin (control [n ¼ 85]). Eligible patients receivedTrial Registration: An Open-Label, Multicenter, Randomized,
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(cixutumumab arm) or without it (control arm). The pri-
mary end point was progression-free survival. Secondary
end points assessed overall survival, objective response
rate, and safety. Survival was analyzed by the Kaplan-Meier
method and Cox proportional hazard model. Exploratory
correlative analyses were also performed.
Results: The mean age of the intent-to-treat population
(n ¼ 172) was 59 years (range 32–83). Median progression-
free survival was 5.45 months with cixutumumab versus
5.22 months in the control (hazard ratio ¼ 1.15, 95%
conﬁdence interval: 0.81–1.61; p ¼ 0.44). Median overall
survival was 11.33 months with cixutumumab versus 10.38
months in the control (hazard ratio ¼ 0.93, 95% conﬁdence
interval: 0.64–1.36). Objective response rate did not differ
between treatments (p ¼ 0.338). Grade 3 or 4 hyperglyce-
mia occurred at a higher rate with cixutumumab than in the
control (9.4% versus 1.2%). One death possibly related to
cixutumumab occurred.
Conclusions: Efﬁcacy was not improved in patients with
nonsquamous NSCLC when cixutumumab was added to
pemetrexed/cisplatin. Combination therapy was well
tolerated and no new safety concerns were reported.
 2016 International Association for the Study of Lung
Cancer. Published by Elsevier Inc. This is an open access
article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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Introduction
Nonsquamous (NSq) NSCLC accounts for most pa-
tients with NSCLC and often presents as advanced/
metastatic disease at diagnosis. On average, the median
survival time of untreated patients with advanced NSq
NSCLC is approximately 4 months after diagnosis.
However, for patients with good performance status,
ﬁrst-line platinum-based chemotherapy improves both
survival and quality of life.1
Platinum-based doublets have shown no signiﬁcant
differences in objective response rate (ORR), progression-
free survival (PFS), or overall survival (OS).2,3 Other
clinical factors not considered with traditional chemo-
therapy, such as histologic subtype, may also inﬂuence
clinical outcome. Patients with advanced NSCLC with a
nonsquamous histologic subtype beneﬁted more from
pemetrexed/cisplatin than cisplatin/gemcitabine in
terms of OS (hazard ratio [HR] 0.81; p ¼ 0.005), whereas
PFS was similar between arms.4 This evidence provided a
rationale for the current patient population in addition to
the need for effective treatments for patients with NSq
NSCLC who may not have oncogenic alterations.It is clear that type 1 insulin-like growth factor (IGF-I)
receptor (IGF-IR) has signiﬁcant implications in NSCLC.
Cixutumumab (IMC-A12 [Eli Lilly and Company, Indi-
anapolis, IN]), a human immunoglobulin G monoclonal
antibody, blocks IGF-IR activity and inhibits tumor sur-
vival and growth in numerous solid tumor types,
including lung cancer, and in human tumor xenograft
models in vivo, both alone5 and combined with chemo-
therapy.6 However, the clinical beneﬁt of adding cix-
utumumab to chemotherapy in patients with advanced
NSq NSCLC is unknown.
This open-label, multicenter, randomized phase II
study assessed whether adding cixutumumab to peme-
trexed/cisplatin was superior to pemetrexed/cisplatin
as ﬁrst-line therapy in patients with advanced NSq
NSCLC. Biomarkers potentially predictive of cix-
utumumab efﬁcacy were also evaluated.
Materials and Methods
Patients and Study Design
An overview of the study design and treatment plan
has been fully described in Figure 1. Before enrollment,
an institutional review board reviewed and approved
the study protocol. Patients who met the eligibility
criteria (Fig. 1) were enrolled in the study. Intravenous
(IV) cixutumumab infusions were administered ﬁrst,
followed by an IV pemetrexed infusion 1 hour later and
an IV cisplatin infusion 30 minutes after pemetrexed. All
patients received vitamin B12, folic acid supplementation,
and prophylactic dexamethasone. Patients continued
maintenance therapy until disease progression, unac-
ceptable toxicity, noncompliance, or withdrawal of
consent.
Statistical Analysis
A superiority test comparing PFS was planned for
the patients (n ¼ 156). A median PFS of 5.3 months in
the control arm was assumed with an expected median
PFS of 7.16 months in the cixutumumab arm (HR of
cixutumumab/control ¼ 0.74). With a power of 80%
(one-sided signiﬁcance level of 20%, 1:1 ratio) to
detect an HR of 0.74, 125 events were required for
analysis.
The HR of cixutumumab/control for PFS was deter-
mined using the Cox’s proportional hazard model. PFS,
OS, and time to progressive disease were estimated us-
ing the Kaplan-Meier method and differences assessed
by log-rank test. The ORRs were compared using Fisher’s
exact test. Radiographic imaging assessed the percentage
change in tumor size from baseline to the end of cycle 2;
comparisons were analyzed using a t test. Safety was
assessed using the Common Terminology Criteria for
Adverse Events, version 4.0.
Inclusion Criteria 
• ≥ 18 years of age
• Histologic or cytologic
NSq-NSCLC diagnosis
• ECOG PS 0 or 1 
• Diagnosis of Stage IV
NSq-NSCLC or 
metastatic, recurrent
disease
• Adequate bone marrow
reserve, renal and hepatic
function, and fasting 
serum glucose and 
hemoglobin A1c levels
Exclusion Criteria 
• Other cancer diagnoses
• Previous chemotherapy 
• Treatment with 
pemetrexed or other IGF-
IR/EGFR agents
• Pregnancy 
• Leptomeningeal disease
• Diabetes mellitus
• Other intercurrent
illnesses/infections
Randomization
1:1 
Cixutumumab Arm:
20 mg/kg cixutumumab 
500 mg/m2 pemetrexed
75 mg/m2 cisplatin
Control Arm:
500 mg/m2 pemetrexed
75 mg/m2 cisplatin
INDUCTION
(every 21 days up to 6 cycles) 
Cixutumumab Arm:
20 mg/kg cixutumumab 
500 mg/m2 pemetrexed
Control Arm:
500 mg/m2 pemetrexed
MAINTENANCE 
(every 21 days until discontinuation) 
Figure 1. Study design. ECOG PS, Eastern Cooperative Oncology Group Performance Status; IGF-IR, type 1 insulin-like growth
factor receptor; NSq, nonsquamous.
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netics (PK) analysis of cixutumumabwere also performed
(see Supplemental Digital Content for analysis methods).
Results
Clinical Efﬁcacy
A total of 172 patients were randomized (cix-
utumumab [n ¼ 87] versus control [n ¼ 85]). Patients
discontinued treatment in the cixutumumab and control
arms because of progressive disease (40% and 37%,
respectively), adverse events (AEs) (20% and 15%,
respectively), and death (11% for both arms). Baseline
patient and disease characteristics (Table 1) of the
intent-to-treat population were similar between arms.
The median PFS was 5.45 months with cixutumumab
and 5.22 months with control (HR ¼ 1.15, 95% conﬁ-
dence interval [CI]: 0.81–1.61), with no statistically
signiﬁcant difference between arms (Fig. 2A). Similarly,
no statistically signiﬁcant difference in OS between arms
was observed, but the median OS (Fig. 2B) was numer-
ically higher with cixutumumab than control (11.33
months versus 10.38 months, HR ¼ 0.93, 95% CI:
0.64–1.36).
The ORR rates were 37.9% and 30.6% with cix-
utumumab and control, respectively (p ¼ 0.338). Best tu-
mor responses were similar between arms (Table 2), with
more patients experiencing a partial response (37.9%versus 30.6%) or progressive disease (16.1% versus
12.9%) with cixutumumab than control. There was a
similar percentage of clinical beneﬁt responders between
arms (p ¼ 0.511).
The median time to progressive disease was 6.05
months with both cixutumumab (95% CI: 5.32–7.79)
and control (95% CI: 4.93–7.89). In addition, although
the mean percent change from baseline in tumor size
was greater with cixutumumab (mean ± SD ¼ –23.88 ±
18.86) versus control (–16.04 ± 26.14), the difference
was not statistically signiﬁcant.
Safety
The safety analyses included 166 patients (cix-
utumumab [n ¼ 85] versus control [n ¼ 81]). As
shown in Table 3, grade 3 or 4 treatment-emergent
AEs possibly related to treatment occurred more
frequently with cixutumumab (56.5%) than control
(43.2%). As expected, hyperglycemia (all grades)
occurred at a higher rate with cixutumumab (41.2%)
than control (7.4%). Dehydration (all grades), a
known effect of cisplatin treatment, was also more
frequently reported with cixutumumab (17.7%) than
control (6.2%).
Rates of discontinuation due to serious AEs (SAEs)
possibly related to any study drug were similar between
arms (cixutumumab, 7.1%; control, 8.6%). Three patients
Table 1. Patient Demographics and Disease Characteristics
at Baseline (Intent-to-Treat Population)
Characteristic
Cixutumumab Arm
(n ¼ 87)
Control Arm
(n ¼ 85)
Sex, n (%)
Male 54 (62.1) 53 (62.4)
Race, n (%)
White 81 (97.6) 80 (96.4)
Nonwhite 2 (2.4) 3 (3.6)
Missing 4 (4.6) 2 (2.4)
Age, y
Mean ± SD 59.5 ± 9.87 59.3 ± 9.96
Median 59 60
ECOG performance
status, n (%)
0 41 (47.1) 41 (48.2)
1 46 (52.9) 44 (51.8)
Basis for pathological
diagnosis, n (%)
Histological 74 (85.1) 74 (87.1)
Cytological 13 (14.9) 11 (12.9)
Histological type at
entry or initial
diagnosis, n (%)
Adenocarcinoma 80 (92.0) 75 (88.2)
Large cell 1 (1.1) 0
Other 6 (6.9) 10 (11.8)
Disease stage at initial
diagnosis, n (%)
IA/IB 2 (2.2) 0
IIIA 5 (5.7) 6 (7.1)
IIIB 2 (2.3) 1 (1.2)
IV 78 (89.7) 78 (91.8)
Smoking Status, n (%)
Never 15 (17.2) 13 (15.3)
Ever 72 (82.8) 72 (84.7)
Prior therapies, n (%)a
Surgery 13 (14.9) 14 (16.5)
Radiotherapy 17 (19.5) 22 (25.9)
Systemic therapy 3 (3.4) 7 (8.2)
aPatients may have received more than one prior therapy.
ECOG, Eastern Cooperative Oncology Group.
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led to discontinuation (one SAE each of myocardial
infarction, pancytopenia, and sepsis). Four patients in
each arm died and the deaths were considered possibly
related to any study drug; one death (due to sepsis) was
possibly cixutumumab related.PK
PK analysis of cixutumumab was performed using
available serum concentration–time data (n ¼ 83 [see
Supplementary Text]). Overall, serum concentrations of
cixutumumab increased after each cixutumumab infu-
sion and accumulation of cixutumumab was observed
(Supplementary Fig. 1). Cixutumumab clearance was low(0.02 L/h) and it had a long terminal elimination half-life
(8 days [see Supplementary Table 1]).Exploratory Correlative Analyses
Circulating and tumor-speciﬁc candidate biomarkers
were also evaluated (Supplementary text and
Supplementary Tables 2–5). No statistically signiﬁcant
interactions were demonstrated; however, compared
with the control arm, numerically longer PFS, OS, or both
PFS and OS were observed in cixutumumab-treated pa-
tients with low circulating total IGF-I levels (25th
percentile cutpoint), tumor protein p53 gene (TP53)
mutations, and high type 1 insulin-like growth factor
receptor/insulin receptor ratio (75th percentile cut-
point) in tumor tissue, respectively.
Discussion
This phase II study failed to support the hypothesis
that adding cixutumumab to pemetrexed/cisplatin was
superior to pemetrexed/cisplatin alone as ﬁrst-line ther-
apy in patients with advanced, metastatic NSq NSCLC. No
new safety concerns were reported. Similarly, studies of
cixutumumab combined with other chemotherapies as a
ﬁrst-line therapy in other solid tumors have also found
little to no beneﬁt from adding cixutumumab.7,8
The lack of efﬁcacy observed may be due, at least in
part, to the administration sequence of IGF-IR inhibitors
and chemotherapeutic agents.9 In breast cancer cells,
growth inhibition improves when chemotherapy (doxo-
rubicin and gemcitabine) is administered before IGF-IR
inhibition, and an opposite effect occurs with the reverse
administration.10,11 Here, cixutumumab was administered
ﬁrst followedbypemetrexed/cisplatin, all on the sameday.
The addition of cixutumumab to pemetrexed/cisplatin
chemotherapy did not lead to any signiﬁcant increase in
toxicity, except for hyperglycemia, which is common
among patients receiving cixutumumab. Similar safety
proﬁles have been observed when cixutumumab was
combined with mitotane7 and gemcitabine and erloti-
nib.12 Dose-limiting toxicities were reported when erlo-
tinib and cixutumumab were combined in patients with
NSCLC, a ﬁnding supported when other anti–IGF-IR
monoclonal antibodies were unsuccessfully combined
with full-dose erlotinib in patients with NSCLC.8
Clinical biomarkers may also predict clinical outcomes
for IGF-IR–directed therapy. Because IGF-IR monoclonal
antibodies failed to demonstrate signiﬁcant clinical beneﬁt
in general patient populations,13 studies are exploring the
relationship between circulating biomarkers and clinical
outcome. Elevated insulin-like growth factor binding
protein-1 correlatedwith improvedPFS (p¼ 0.009) andOS
(p ¼ 0.003) in patients with advanced hepatocellular
Figure 2. (A) Progression-free survival and (B) overall survival Kaplan-Meier curves for the cixutumumab (red) and control
(blue) treatment arms in the intent-to-treat population. vs, versus; HR, hazard ratio; CI, conﬁdence interval.
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addition, low IGF-I baseline levels were associated with
signiﬁcantly shorter OS with a ﬁgitumumab combination
therapy regimen versus control (P ¼ 0.01), whereas
patients with high baseline levels of glycosylated hemo-
globin had a lowermedianOSwith combinedﬁgitumumab
therapy versus control (p ¼ 0.05).15 On the basis of ourexploratory biomarker analysis, numerically longer PFS,
OS, or both PFS and OS were recorded in cixutumumab-
treated patients with low circulating total IGF-I levels,
TP53 mutations, and high tumor IGF-IR/IR ratio, respec-
tively. Of note, the biomarker analysis was limited due to
the small sample size in subgroups that were deﬁned by
marker class by treatment and a high censoring rate in OS.
Table 2. Best Overall Tumor Response
Response
Cixutumumab Arm
(n ¼ 87)
Control Arm
(n ¼ 85)
p Value
(Fisher’s Exact Test)
Complete response, n 0 0
Partial response, n 33 26
% (95% CI) 37.9 (27.7–48.1) 30.6 (20.8–40.4)
Stable disease, n 25 35
% (95% CI) 28.7 (19.2–38.2) 41.2 (30.7–51.6)
Progressive disease, n 14 11
% (95% CI) 16.1 (8.4–23.8) 12.9 (5.8–20.1)
Not assessed, n (%) 15 (17.2) 13 (15.3)
Overall response rate
CR þ PR responders, n 33 26 0.338
% (95% CI, exact method) 37.9 (27.7–49.0) 30.6 (21.0–41.5)
Disease control rate
CRþPRþ stable disease, n 58 61 0.511
% (95% CI, exact method) 66.7 (55.7–76.4) 71.8 (61.0–81.0)
CI, conﬁdence interval; CR, complete response, PR, partial response.
388 Novello et al Journal of Thoracic Oncology Vol. 12 No. 2In summary, cixutumumab added to pemetrexed/
cisplatin does not improve clinical outcome as measured
in PFS in patients with NSq NSCLC as a ﬁrst-line therapy.
Our ﬁndings corroborate the work of others and suggest
that IGF-IR inhibition is largely ineffective in patients
with NSq NSCLC. However, because none of the IGF-IR
clinical studies enriched for a speciﬁc biomarker popu-
lation, it is plausible that only select patients with NSq
NSCLC beneﬁt from the anti–IGF-IR antibodies. The
predictive potential of the IGF-IR/IR ratio, TP53 muta-
tional status, and total IGF-I levels warrant furtherTable 3. Treatment-Emergent AEs Possibly Related to Any Trea
Population)
Adverse Event
Cixutumumab Arm
(n ¼ 85)
CTCAE Term All Grades
Grade
3 4
Patients with 1 TEAE 82 (96.5) 39 (45.9) 9 (
Anemia 24 (28.2) 8 (9.4) 0
Anorexia 23 (27.1) 6 (7.1) 0
Constipation 14 (16.5) 1 (1.2) 0
Creatinine level increased 8 (9.4) 1 (1.2) 0
Dehydration 15 (17.7) 4 (4.7) 1 (
Diarrhea 15 (17.7) 2 (2.4) 0
Fatigue 33 (38.8) 7 (8.2) 0
Hyperglycemia 35 (41.2) 7 (8.2) 1 (
Mucositis, oral 22 (25.9) 3 (3.5) 0
Nausea 18 (21.2) 4 (4.7) 0
Neutrophil count decreased 25 (29.4) 12 (14.1) 2 (
Platelet count decreased 15 (17.6) 4 (4.7) 3 (
Vomiting 30 (35.3) 7 (8.2) 0
Weight loss 10 (11.8) 0 0
White blood cell count decreased 11 (12.9) 0 4 (
Note: Data are reported as n (%) for the highest-grade treatment-emergent adv
AE, adverse event; CTCAE, Common Terminology Criteria for Adverse Events; Tinvestigation in clinical trials with a biomarker-driven
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